This study, and others (6–8), based on bulk tumour or single-cell sequencing have identified molecular markers (9) such as, methylation status of MGMT promoter and w/t IDH-1 status that have been widely explored as prognostic biomarkers for therapy responsiveness (10, 11). This evidence concerns the gene MGMT and neoplasm.